Overview

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Status:
RECRUITING

Trial end date:
2033-01-01

Target enrollment:

Participant gender:

Summary

Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.

Phase:

PHASE1

Details

Lead Sponsor:

RayzeBio, Inc.